The theranostic optimization of PSMA-GCK01 does not compromise the imaging characteristics of [99mTc]Tc-PSMA-GCK01 compared to dedicated diagnostic [99mTc]Tc-EDDA/HYNIC-iPSMA in prostate cancer
Radiolabeled PSMA-ligands play a major role in today’s nuclear medicine. Since approval of [177Lu]Lu-PSMA-617 for therapy of metastatic prostate cancer, availability of 177Lu became bottleneck of supply due to the high demand. Recently, a theranostic PSMA-ligand, PSMA-GCK01, was developed which can...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
08 December 2023
|
| In: |
Molecular imaging & biology
Year: 2023, Pages: 1-9 |
| ISSN: | 1860-2002 |
| DOI: | 10.1007/s11307-023-01881-y |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s11307-023-01881-y Verlag, kostenfrei, Volltext: https://link.springer.com/article/10.1007/s11307-023-01881-y 
|
| Verfasserangaben: | Eduards Mamlins, Lara Scharbert, Jens Cardinale, Maria Krotov, Erik Winter, Hendrik Rathke, Birgit Strodel, Alfred O. Ankrah, Mike Sathekge, Uwe Haberkorn, Clemens Kratochwil, Frederik L. Giesel |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 187952726X | ||
| 003 | DE-627 | ||
| 005 | 20240307025143.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240130s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11307-023-01881-y |2 doi | |
| 035 | |a (DE-627)187952726X | ||
| 035 | |a (DE-599)KXP187952726X | ||
| 035 | |a (OCoLC)1425207222 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Mamlins, Eduards |e VerfasserIn |0 (DE-588)1139848100 |0 (DE-627)897716248 |0 (DE-576)493488790 |4 aut | |
| 245 | 1 | 4 | |a The theranostic optimization of PSMA-GCK01 does not compromise the imaging characteristics of [99mTc]Tc-PSMA-GCK01 compared to dedicated diagnostic [99mTc]Tc-EDDA/HYNIC-iPSMA in prostate cancer |c Eduards Mamlins, Lara Scharbert, Jens Cardinale, Maria Krotov, Erik Winter, Hendrik Rathke, Birgit Strodel, Alfred O. Ankrah, Mike Sathekge, Uwe Haberkorn, Clemens Kratochwil, Frederik L. Giesel |
| 264 | 1 | |c 08 December 2023 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 30.01.2024 | ||
| 520 | |a Radiolabeled PSMA-ligands play a major role in today’s nuclear medicine. Since approval of [177Lu]Lu-PSMA-617 for therapy of metastatic prostate cancer, availability of 177Lu became bottleneck of supply due to the high demand. Recently, a theranostic PSMA-ligand, PSMA-GCK01, was developed which can be labeled either diagnostically with 99mTc or therapeutically with 188Re with both nuclides available from well-known generator systems. This novel tracer might aid to overcome aforementioned supply limitations. In this investigation, the biodistribution and general imaging characteristics of [99mTc]Tc-PSMA-GCK01 were compared with the diagnostic reference compound [99mTc]Tc-EDDA/HYNIC-iPSMA in patients with advanced stage prostate cancer. In addition, the binding of both ligands to PSMA was analyzed at the molecular level using molecular docking. | ||
| 650 | 4 | |a Prostate cancer | |
| 650 | 4 | |a PSMA-GCK01 | |
| 650 | 4 | |a SPECT | |
| 650 | 4 | |a Technetium-99 m | |
| 650 | 4 | |a Theranostic | |
| 700 | 1 | |a Scharbert, Lara |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cardinale, Jens |d 1981- |e VerfasserIn |0 (DE-588)1030356505 |0 (DE-627)735121206 |0 (DE-576)378165941 |4 aut | |
| 700 | 1 | |a Krotov, Maria |e VerfasserIn |4 aut | |
| 700 | 1 | |a Winter, Erik |d 1991- |e VerfasserIn |0 (DE-588)1196751358 |0 (DE-627)167862246X |4 aut | |
| 700 | 1 | |a Rathke, Hendrik |d 1986- |e VerfasserIn |0 (DE-588)1151445495 |0 (DE-627)1011715392 |0 (DE-576)497748223 |4 aut | |
| 700 | 1 | |a Strodel, Birgit |d 1973- |e VerfasserIn |0 (DE-588)130006890 |0 (DE-627)48692002X |0 (DE-576)297946838 |4 aut | |
| 700 | 1 | |a Ankrah, Alfred O. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sathekge, Mike |e VerfasserIn |0 (DE-588)1203400837 |0 (DE-627)1688473130 |4 aut | |
| 700 | 1 | |a Haberkorn, Uwe |d 1959- |e VerfasserIn |0 (DE-588)1022913905 |0 (DE-627)717331245 |0 (DE-576)366166352 |4 aut | |
| 700 | 1 | |a Kratochwil, Clemens |d 1978- |e VerfasserIn |0 (DE-588)134026276 |0 (DE-627)559871686 |0 (DE-576)300262787 |4 aut | |
| 700 | 1 | |a Giesel, Frederik L. |d 1970- |e VerfasserIn |0 (DE-588)129031240 |0 (DE-627)387883878 |0 (DE-576)297457071 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular imaging & biology |d Cham : Springer Nature Switzerland, 2002 |g (2023), Seite 1-9 |h Online-Ressource |w (DE-627)348231075 |w (DE-600)2079211-6 |w (DE-576)283406909 |x 1860-2002 |7 nnas |a The theranostic optimization of PSMA-GCK01 does not compromise the imaging characteristics of [99mTc]Tc-PSMA-GCK01 compared to dedicated diagnostic [99mTc]Tc-EDDA/HYNIC-iPSMA in prostate cancer |
| 773 | 1 | 8 | |g year:2023 |g pages:1-9 |g extent:9 |a The theranostic optimization of PSMA-GCK01 does not compromise the imaging characteristics of [99mTc]Tc-PSMA-GCK01 compared to dedicated diagnostic [99mTc]Tc-EDDA/HYNIC-iPSMA in prostate cancer |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s11307-023-01881-y |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://link.springer.com/article/10.1007/s11307-023-01881-y |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20240130 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 129031240 |a Giesel, Frederik L. |m 129031240:Giesel, Frederik L. |d 910000 |d 911400 |d 50000 |e 910000PG129031240 |e 911400PG129031240 |e 50000PG129031240 |k 0/910000/ |k 1/910000/911400/ |k 0/50000/ |p 12 |y j | ||
| 998 | |g 134026276 |a Kratochwil, Clemens |m 134026276:Kratochwil, Clemens |d 910000 |d 911400 |e 910000PK134026276 |e 911400PK134026276 |k 0/910000/ |k 1/910000/911400/ |p 11 | ||
| 998 | |g 1022913905 |a Haberkorn, Uwe |m 1022913905:Haberkorn, Uwe |d 910000 |d 911400 |e 910000PH1022913905 |e 911400PH1022913905 |k 0/910000/ |k 1/910000/911400/ |p 10 | ||
| 998 | |g 1151445495 |a Rathke, Hendrik |m 1151445495:Rathke, Hendrik |p 6 | ||
| 998 | |g 1196751358 |a Winter, Erik |m 1196751358:Winter, Erik |d 910000 |d 911400 |e 910000PW1196751358 |e 911400PW1196751358 |k 0/910000/ |k 1/910000/911400/ |p 5 | ||
| 998 | |g 1030356505 |a Cardinale, Jens |m 1030356505:Cardinale, Jens |p 3 | ||
| 999 | |a KXP-PPN187952726X |e 4472387751 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"name":{"displayForm":["Eduards Mamlins, Lara Scharbert, Jens Cardinale, Maria Krotov, Erik Winter, Hendrik Rathke, Birgit Strodel, Alfred O. Ankrah, Mike Sathekge, Uwe Haberkorn, Clemens Kratochwil, Frederik L. Giesel"]},"person":[{"display":"Mamlins, Eduards","given":"Eduards","family":"Mamlins","role":"aut"},{"display":"Scharbert, Lara","given":"Lara","role":"aut","family":"Scharbert"},{"given":"Jens","display":"Cardinale, Jens","family":"Cardinale","role":"aut"},{"given":"Maria","display":"Krotov, Maria","family":"Krotov","role":"aut"},{"given":"Erik","display":"Winter, Erik","role":"aut","family":"Winter"},{"display":"Rathke, Hendrik","given":"Hendrik","family":"Rathke","role":"aut"},{"given":"Birgit","display":"Strodel, Birgit","family":"Strodel","role":"aut"},{"display":"Ankrah, Alfred O.","given":"Alfred O.","family":"Ankrah","role":"aut"},{"display":"Sathekge, Mike","given":"Mike","role":"aut","family":"Sathekge"},{"family":"Haberkorn","role":"aut","given":"Uwe","display":"Haberkorn, Uwe"},{"role":"aut","family":"Kratochwil","given":"Clemens","display":"Kratochwil, Clemens"},{"family":"Giesel","role":"aut","given":"Frederik L.","display":"Giesel, Frederik L."}],"recId":"187952726X","note":["Gesehen am 30.01.2024"],"title":[{"title_sort":"theranostic optimization of PSMA-GCK01 does not compromise the imaging characteristics of [99mTc]Tc-PSMA-GCK01 compared to dedicated diagnostic [99mTc]Tc-EDDA/HYNIC-iPSMA in prostate cancer","title":"The theranostic optimization of PSMA-GCK01 does not compromise the imaging characteristics of [99mTc]Tc-PSMA-GCK01 compared to dedicated diagnostic [99mTc]Tc-EDDA/HYNIC-iPSMA in prostate cancer"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"eki":["187952726X"],"doi":["10.1007/s11307-023-01881-y"]},"physDesc":[{"extent":"9 S."}],"relHost":[{"language":["eng"],"part":{"pages":"1-9","extent":"9","text":"(2023), Seite 1-9","year":"2023"},"note":["Gesehen am 29.07.2020"],"pubHistory":["4.2002 -"],"disp":"The theranostic optimization of PSMA-GCK01 does not compromise the imaging characteristics of [99mTc]Tc-PSMA-GCK01 compared to dedicated diagnostic [99mTc]Tc-EDDA/HYNIC-iPSMA in prostate cancerMolecular imaging & biology","type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"348231075","title":[{"title_sort":"Molecular imaging & biology","title":"Molecular imaging & biology","subtitle":"MIB ; the official journal of the Academy of Molecular Imaging"}],"id":{"zdb":["2079211-6"],"eki":["348231075"],"issn":["1860-2002"]},"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedDisp":"2002-","publisher":"Springer Nature Switzerland ; Elsevier Science","publisherPlace":"Cham ; Amsterdam [u.a.]","dateIssuedKey":"2002"}]}],"origin":[{"dateIssuedDisp":"08 December 2023","dateIssuedKey":"2023"}]} | ||
| SRT | |a MAMLINSEDUTHERANOSTI0820 | ||